Brief: Calmark: Neo-Bilirubin To Obtain CE Mark Approval In January 2020
Dec 23 (Reuters) - Calmark Sweden AB CALMAb.TE :
* CALMARK'S PRODUCT NEO-BILIRUBIN WILL OBTAIN CE MARK
APPROVAL IN
JANUARY 2020
* PARTIAL STUDY OF VERIFICATION AND VALIDATION PROCESS STILL
REMAINS, AND STUDY AT SÖDERSJUKHUSET IS NOT FINISHED
Source text for Eikon: ID:nWkr5sGNzg
Further company coverage: CALMAb.TE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Calmark Sweden AB
See all newsBrief: Calmark Sweden AB Says Signs Distributor Agreement for India Regarding COVID-19-LDH
Brief: Calmark Signs Distributor Agreement With Enox Pharma For Five Key Markets In The Middle East
Brief: Calmark Sweden Q4 Oper Loss Widens To SEK 4.0 Mln
Brief: Calmark Sweden Signs Distribution Deal With LabForce In Switzerland
Brief: Calmark Sweden Raises SEK 26.5 Mln In Oversubscribed Rights Issue